SAVE \$200! Register by December 20





Models for *de novo* Design



Predicting Developability and Optimization Using Machine Learning



Machine Learning in Early Discovery



Training Data Generation and Quality

NOBEL LAUREATE



David A. Baker, PhD University of Washington



Rebecca Croasdale-Wood, PhD AstraZeneca

PLENARY KEYNOTES

EVENT-AT-A-GLANCE



Victor Greiff, PhD University of Oslo

BioLogicSummit.com



Marissa Mock, PhD Amgen Inc.



Vladimir Gligorijević, PhD Genentech









木曽印路

Includes Access to

Training SEMINARS By Cambridge Healthtech Institute

MONDAY, JANUARY 13, 2025 | 9am-6pm

All training seminars take place in-person only

TS1A: Introduction to Machine Learning for Biologics Design

Instructors:

Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada Francis Gaudreault, PhD, Associate Research Officer, Human Health Therapeutics, National Research Council Canada

This course offers an introduction to concepts, strategies, and machine learning methods used for biologics design. It includes presentations and demonstrations of the methods used in the field, covering techniques such as triaging sequences, modulating affinity, and designing antibody libraries, along with increasing manufacturability. The course is directed at scientists new to the field and protein engineers wanting an introduction to how machine learning can aid in guiding biologics design.

TS2A: Implementing Artificial Intelligence and Computational Tools in Biopharmaceutical R&D Instructor:

Ryan Peckner, PhD, Director, Machine Learning, Seismic Therapeutic Artificial intelligence and other computational techniques have revolutionized biopharma research over the past two decades, leading to the solutions of fundamental problems such as protein folding and the acceleration of numerous aspects of biopharma R&D. This seminar will survey the landscape of Al and computational tools with an emphasis on the steps needed to implement Al-based workflows and programs in biotherapeutic research organizations. We will examine case studies and interactive demonstrations in a range of application areas in which Al has led to acceleration and innovation, including identifying novel drug targets, predicting protein structure, designing small molecules and antibodies, and optimizing biopharmaceutical manufacturing processes.



Interactive Elements at the BioLogic Summit

In addition to podium presentations, this event will include a significant number of interactive elements, including moderated discussions, and single day training seminars. Interactive forums play an integral role in facilitating networking with potential collaborators and provide an opportunity to be part of a group problem-solving endeavor.

Co-located Event: January 13-16, 2025 | San Diego, CA + Virtual Hilton Bayfront

EXAMPLE 24th Annual Constant of Const

Creating Antibodies in Silico

TUESDAY, JANUARY 14

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:20 Organizer's Remarks

Christina Lingham, Executive Director, Conferences and Fellow, Cambridge Healthtech Institute

Kent Simmons, Senior Conference Director, Cambridge Healthtech Institute



8:25 Plenary Keynote Introduction Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi



8:30 The State of the Art for Antibody Structure Prediction

Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo

Antibody structure prediction is pivotal for understanding antibody function and for enabling *in silico* antibody design. This lecture will outline current key advances as well as unresolved challenges in antibody structure prediction.



9:00 Design of New Protein Functions Using Deep Learning

David A. Baker, PhD, Henrietta & Aubrey David Endowed Professor, Biochemistry, University of Washington

Proteins are biology's workhorses. Our goal is to create new proteins that address current-day problems not faced during evolution. Rather than modify naturally occurring proteins, we design new ones from scratch to optimally solve the problem at hand. Increasingly, we develop and use deep learning methods to generate protein sequence, structure, and function. We then characterize these designed molecules experimentally. In this talk, I will describe several recent projects.

LATEST TOOLS AND APPROACHES FOR DESIGNING PROTEINS USING MODELS

10:00 Chairperson's Opening Remarks

Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi



10:05 KEYNOTE PRESENTATION: Accelerating Biologic Drug Discovery with Al: Advancements and Challenges in *de novo* Antibody Design Per Greisen, PhD, President, BioMap

The urgent need for novel biologics demands accelerated drug discovery. We leverage AI to expedite therapeutic antibody development, showcasing our progress in *de novo* design of VHH and mAbs targeting specific epitopes. We'll discuss the strengths and limitations of current AI algorithms, challenges in translating designs into functional molecules, and strategies to refine these algorithms for improved *de novo* biologic design success.

10:35 Developing and Implementing an Effective IP Strategy for an Al/ ML-Driven Biologics Therapeutic Program

Matt Wheeler, PhD, JD, Senior Associate, Patents and Innovations Group, Wilson Sonsini Goodrich & Rosati

This talk will focus on understanding IP rights, inventorship, and ownership of AI/ML-based inventions including platform aspects and therapeutic modalities. Deciding between patenting and maintaining trade secret aspects of the platform and modalities will be discussed. It will review life cycle management strategy for a biologics therapeutic program and Freedom to Operate.

11:05 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

11:20 Steering Protein Language Models for Functional Protein Design Jeffrey Ruffolo, PhD, Head of Protein Design, Profluent Bio

Protein language models trained on evolutionarily diverse sequences implicitly

model the sequence-function landscape of proteins. These models learn to generate diverse sequences, but must be steered for protein design tasks. We first discuss the generation of diverse CRISPR-Cas effectors for genome editing applications through fine-tuning on curated natural sequences. Next, we present a strategy for steering protein language models through conditioning on structural and functional context.

11:50 De novo Designed Proteins Neutralize Lethal Snake Venom Toxins

Susana Vazquez Torres, PhD Student, Protein Design, University of Washington Here, we use deep learning methods to *de novo* design proteins to bind short- and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtain protein designs with remarkable thermal stability, high binding affinity, and near-atomic level agreement with the computational models. The designed proteins effectively neutralize all three 3FTx sub-families *in vitro* and protect mice from a lethal neurotoxin challenge.

12:20 pm Enjoy Lunch on Your Own

1:30 Refreshment Break in the Exhibit Hall with Poster Viewing

NEXT STEPS FOR PREDICTING MOLECULAR DYNAMICS AND FUNCTIONAL EFFECTS OF MUTATIONS

2:00 Chairperson's Remarks

Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo

2:05 Deep Learning Guided Design of Dynamic Proteins

Tanja Kortemme, PhD, Professor, Bioengineering & Therapeutic Sciences, University of California, San Francisco

Methods from artificial intelligence can now "write" proteins *de novo*, without starting from proteins found in nature. I will discuss our recent progress with developing deep learning models for *de novo* protein design, demonstrating that they generalize beyond the training space, and applying them to difficult problems, including atomically accurate design of dynamic proteins. Exciting frontiers lie in constructing synthetic cellular signaling from the ground up using *de novo* proteins.

2:35 Machine Learning Coarse-Grained Potentials of Protein Thermodynamics

Klara Bonneau, PhD Student, Computational Biophysics, Freie Universität Berlin Coarse-grained (CG) models are an alternative to the expensive all-atom models, but reaching high predictive power has been a longstanding challenge. By combining deep learning methods with a diverse training set of protein simulations, we have developed a CG force field which can be used for molecular dynamics on new sequences not used during model parametrization. This showcases the feasibility of a universal and efficient CG model for proteins.

3:05 Decoding Molecular Mechanisms for Loss of Function Variants Matteo Cagiada, PhD, Postdoctoral Fellowship Program, Novo Nordisk Foundation, University of Copenhagen

Proteins are essential for cellular function, and missense variants can cause genetic disorders by destabilizing proteins or disrupting key interactions. While prediction of deleterious variants has progressed, understanding of the molecular mechanisms behind these variants remains limited. Thanks to advances in sequence- and structure-based computational predictors, we can now unravel the molecular mechanisms behind loss-of-function and quantify the role of stability in disrupting protein function.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Interactive Breakout Discussions

TABLE 2: How Open Competitions Provide Valuable Benchmarking to Novel Technologies

Andrew R.M. Bradbury, MD, PhD, CSO, Specifica, an IQVIA business Matthieu Schapira, PhD, Principal Investigator, Structural Genomics Consortium, Professor, Pharmacology & Toxicology, University of Toronto

- Why benchmarking is needed
- · Designed competitions, and accidental ones

Models for *de novo* Design

Creating Antibodies in Silico

- Lessons from CACHE
- · The Alntibody competition to assess computational methods in antibody discovery

TABLE 3: Designing Functional Proteins Using Generative AI Models

Jeffrey Ruffolo, PhD, Head of Protein Design, Profluent Bio

- · What types of protein design problems are generative AI models useful for?
- ?How should we leverage biophysical principles when using generative AI?
- · When should we use sequence- vs. structure-based models?
- · What types of new data would be most useful for generative AI design platforms?

TABLE 4: AI-Driven Biologics: Accelerating Discovery, Overcoming Challenges

Per Greisen, PhD, President, BioMap

• Motivation: The urgent need for novel biologics is driving the exploration of AI in drug discovery

- Focus: Al's potential in accelerating biologic drug discovery, particularly *de novo* antibody design
- Showcase: Successful Al-driven VHH and mAb designs

 Discussion: Al's strengths in predicting antibody structures, challenges in translating designs into functional molecules, achieving industrial-scale reliability, and closing the gap between computational and experimental results

5:30 PANEL DISCUSSION: Targeted *de novo* and *in silico* Design of Proteins and Peptides

Moderator: Monica L. Fernandez-Quintero, PhD, Staff Scientist, General Inorganic & Theoretical Chemistry, Scripps Research Institute

- What can be designed at this point?
- · What resources need to be realistically invested to get a hit?
- What are the best tools/workflows out there? How do you decide which one to use? *Panelists*:

Bryan Briney, PhD, Assistant Professor, Immunology & Microbial Science, Scripps Research Institute

Jeffrey J. Gray, PhD, Professor & Research Mentor & Outreach Advisor, Chemical & Biomolecular Engineering, Johns Hopkins University

Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo

Wing Ki Wong, PhD, Senior Scientist, Pharmaceutical Research and Development, Large Molecule Research, Roche Diagnostics GmbH

6:30 Networking Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

WEDNESDAY, JANUARY 15

7:45 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks

Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca



8:40 ML-Powered "Lab-in-the-Loop" Approach for Therapeutic Antibody Discovery and Optimization Vladimir Gligorijević, PhD, Senior Director, Al/ML Prescient Design, Genentech

In this talk, I will review our latest machine-learning approaches for antibody design and multi-property optimization that we use in our "Labin-the-Loop" (LitL) system. I will demonstrate how we use our LitL system to overcome some of the critical antibody design challenges and accelerate drug discovery programs.

LATEST TOOLS AND APPROACHES FOR DESIGNING PROTEINS USING MODELS

9:10 Session Break

9:15 Chairperson's Remarks

Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi



9:20 KEYNOTE PRESENTATION: Discovering Safe, Effective Drugs via Learning and Simulation of 3D Structure

Ron Dror, PhD, Associate Professor, Computer Science, Artificial Intelligence Lab, Stanford University

Recent years have seen dramatic advances in both experimental determination and computational prediction of macromolecular structures. These structures hold great promise for the discovery of highly effective drugs with minimal side effects, but structure-based design of such drugs remains challenging. I will describe recent progress toward this goal, using both atomic-level molecular simulations and machine learning on three-dimensional structures.

9:50 AI Tools for Antibody Engineering

Jeffrey J. Gray, PhD, Professor & Research Mentor & Outreach Advisor, Chemical & Biomolecular Engineering, Johns Hopkins University

Al has become increasingly powerful but can be overhyped. Our lab has used Al methods to develop antibody language models, antibody structure prediction models, protein-protein docking models, and antibody design models. I will share recent results, including testing language models' comprehension of biological antibody maturation processes, benchmarking antibody developability models, and bringing physical energies back into Al predictions. Our results suggest how to use Al tools with appropriate caution.

10:20 *De novo* Design of Epitope-Specific Antibodies Against Soluble and Multipass Membrane Proteins with High Specificity, Developability, and Function

Adithya Paramasivam, ML Scientist, Nabla Bio Inc

We present JAM, a generative protein design system that enables fully computational design of antibodies with therapeutic-grade properties for the first time. JAM generates antibodies that achieve double-digit nanomolar affinities, strong early-stage developability profiles, and precise targeting of functional epitopes without experimental optimization. We demonstrate JAM's capabilities across multiple therapeutic contexts, including the first fully computationally designed antibodies to multipass membrane proteins - Claudin-4 and CXCR7.

10:50 Bagel Booth Crawl with Coffee in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

PLENARY KEYNOTE SESSION

11:15 Chairperson's Remarks

Alissa Hummer, DPhil, Postdoctoral Fellow, Stanford University



11:20 Benchmarking and Integrating ML/Al Advancements in Biologics Discovery and Optimisation for Pharma

Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology,

AstraZeneca

11:50 FIRESIDE CHAT WITH PLENARY KEYNOTE



Moderator: Alissa Hummer, DPhil, Postdoctoral Fellow, Stanford University

Panelists:



Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca

12:20 pm Enjoy Lunch on Your Own

1:00 Close of Models for de novo Design Conference



Predicting Developability and Optimization Using Machine Learning

Accelerating the Development of Complex Biotherapeutics

WEDNESDAY, JANUARY 15

NOVEL PREDICTIVE AND GENERATIVE APPROACHES FOR SOLVING REAL-WORLD ENGINEERING CHALLENGES

1:30 pm Chairperson's Remarks

Andrew B. Waight, PhD, Senior Director, Machine Learning, Discovery Biologics & Protein Sciences, Merck Research Labs



1:35 KEYNOTE PRESENTATION: Antibody Optimization Combining Structure-Based Approaches and Deep Learning

Alan Cheng, PhD, Senior Director, Modeling and Informatics, Merck Research Labs

In the discovery of antibody therapeutics, experimental molecular biology and biophysical methods are powerful approaches that can be combined with computational approaches to accelerate identification of better molecules. We share case studies illustrating how the close integration of experimental methods and deep learning can identify new leads and how structure-based and deep learning approaches can be used to optimize molecules for developability properties.

2:05 A Clinically Validated Al-Driven Platform for Designing Smart and Dynamic Antibody Therapeutics

Reshef Shilon, Head of Al, Biolojic Design

Although antibody drugs have great therapeutic benefits, most function primarily as inert antagonists, and don't fulfill the potential of proteins. Biolojic Design's clinically validated Al-driven platform designs dynamic antibodies that are programmed to respond to changes in the environment. In this talk I'll describe Biolojic's Al-platform, which experimentally generates data for Al models and optimizes, simultaneously, multi-antibody properties—which in turn allows the design of smart and dynamic antibodies.

2:35 Refreshment Break in the Exhibit Hall with Poster Viewing

3:10 Delivering Better Clinical Candidates, Faster: Practical Impacts of Machine Learning on Biologics Preclinical Pipeline

Andrew B. Waight, PhD, Senior Director, Machine Learning, Discovery Biologics & Protein Sciences, Merck Research Labs

Al/ML applications to the field of protein engineering have recently generated immense enthusiasm. In addition to protein folding and *de novo* design, statistical and deep learning technologies are revolutionizing many aspects of the biologics therapeutic discovery. We cover some of the real-world use cases for Al/ML applications—from hit identification to lead optimization stages of discovery biologics—that are facilitating the computational identification of high-quality preclinical candidates and improving efficiency.

3:40 Enhancing AI Capabilities through Smart Data Collection and Evolutionary Intelligence in Antibody Development

M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business Exploring the bilateral importance of leveraging strategic data collection and intelligent experimental design to enhance AI capabilities in antibody development. Discussing the utilization of evolutionary intelligence to refine and optimize affinity maturation strategies, leading to the discovery of antibodies with superior binding properties and therapeutic potential.

4:10 Optimizing Antibodies and Related Protein Therapeutics: Bridging AI, Experimental Designs and Developability.



Sridhar Govindarajan, Co Founder & CTO, IT, ATUM

ATUM's antibody platform combines ML/AI with production quality expression systems and robust analytics. Antibodies are designed *in silico*, assisted by AI and knowledge base, synthesized at scale in commercially relevant platforms, and are characterized for functionality and developability features simultaneously. ML models built on these datasets which are built specifically to "learn", are highly predictive and generate new designs for high-specificity antibodies with developability properties for process development, scale-up, and manufacturing.

4:40 Generative and Predictive Machine Learning for Iterative Multi-Objective Therapeutic Antibody Optimization

Hunter Elliott, PhD, Senior Director, Machine Learning, BigHat Biosciences

The path from discovered binder to developable modern antibody therapeutics represents a complex protein engineering challenge. At BigHat, we frame this as a multi-objective Bayesian optimization problem, with machine learning models in-the-loop with a high-throughput wet lab on a weekly build-test-train cycle. We present several case studies of novel predictive and generative ML methods deployed on this platform to solve real-world antibody therapeutic engineering challenges.

5:10 FACILITATED TOWN HALL DISCUSSION

This Town Hall discussion offers delegates the opportunity to participate in an interactive discussion on important themes that were explored during the conference. The co-hosts will facilitate the conversation, and all are welcome to participate, share views and best practices and ask questions of colleagues.

Applying AI to Improve Manufacturability and Developability of Multispecific Biologics

Mahiuddin Ahmed, PhD, President and CSO, VITRUVIAE

Jeffrey J. Gray, PhD, Professor & Research Mentor & Outreach Advisor, Chemical & Biomolecular Engineering, Johns Hopkins University

- Improving humanization and predicting immunogenicity
- Reducing off-target binding
- Predicting aggregation, viscosity, and excipient formulation
- Combining targets for improved efficacy

Wednesday Night Meet-Up

IN PERSON ONLY MEETUP: What Needs to be Done to Make a Pipeline of Mini-Binders More Developable?



Monica L. Fernandez-Quintero, PhD, Staff Scientist, General Inorganic & Theoretical Chemistry, Scripps Research Institute

Wing Ki Wong, PhD, Senior Scientist, Pharmaceutical Research and Development, Large Molecule Research, Roche Diagnostics GmbH

THURSDAY, JANUARY 16

7:45 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:15 Chairperson's Remarks

M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business



8:20 Transforming Therapeutic Protein Engineering Marissa Mock, PhD, Senior Research Director, Amgen Inc. Generative biology is an emerging discipline that integrates artificial intelligence (AI) and machine learning (ML) with advanced life science technologies. The application of

generative biology to protein engineering is accelerating the discovery and design of complex proteins with therapeutic potential—and, maximizing the benefits of these novel technologies will require seamless integration of both wet- and dry-laboratory technologies.

8:50 Session Break

INTEGRATING AI/ML FOR ENHANCED ANTIBODY SELECTION AND DEVELOPABILITY

8:55 Chairperson's Remarks

M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business

9:00 Generative AI-Guided Design of Vaccine Immunogens Reda Rawi, PhD, Staff Scientist and Co-Head, Structural Bioinformatics Core, NIH NIAID



Predicting Developability and Optimization Using Machine Learning

Accelerating the Development of Complex Biotherapeutics

PAIA[®]

Structure-based vaccine design campaigns that aim to stabilize full-length proteins will not succeed when the virus is evading immune response by sequence diversity. In this work, we capitalized on the recent major advanced that have been achieved in protein design using generative AI tools. We *in silico* designed *de novo* proteins that scaffold sequence-conserved epitope regions of the antigens of interest.

9:30 ML Optimization of Candidate Antibody Yields Highly Diverse Sub-Nanomolar Affinity Libraries

Lin Li, PhD, Senior Staff Member, Lincoln Laboratory, Massachusetts Institute of Technology

The design and discovery of early-stage antibody therapeutics is time- and cost-intensive. I will present an end-to-end machine learning-driven single-chain variable fragments (scFv) design framework that uniquely combines large language models, Bayesian optimization, and high-throughput experimentation. The method enables rapid and cost-effective design of thousands of scFvs across all complementary determining regions. The designed antibodies exhibit strong binding affinities, at high levels of diversity, to a given antigen.

10:00 Generation of Early Developability Data for AI/ML - Challenges and Solutions

Sebastian Giehring, PAIA Biotech GmbH

In this presentation, we will critically evaluate the current methods for generating early developability data, identify existing shortcomings, and present innovative high-throughput assays utilizing the plate-based PAIA technology. This method is designed to deliver reliable and unambiguous biophysical developability data, serving as an efficient replacement for time-intensive and laborious HPLC and ELISA methods.

10:15 Al-Driven paratope mapping (KisoSeek[™]): A new paradigm for antibody discovery

Morteza Babaie, Senior Al Scientist, Kisoji Biotechnology Inc

The KisoSeek[™] platform leverages AI-driven paratope mapping to accelerate therapeutic antibody discovery. Integrating autoencoders, structural/ sequence data and large language models to visualize antibody repertoires in multidimensional maps, enabling functional clustering. Built on KisoMouse(R) HCAb immunization libraries, this approach improves the exploration of diversity through various sampling strategies, including probability-based and targeted selections. KisoSeek[™] supports VHH and VH-VL antibodies, driving efficient and versatile candidate selection for therapeutic development.

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 Efficient Evolution of Antibodies from General Protein Language Models

Varun Shanker, MD-PhD Student, Biophysics, Stanford University

This talk will cover how large language models of protein sequences and structures can learn evolutionary rules that help guide the artificial evolution of human antibodies. We will cover how algorithms known as protein language models can guide the affinity maturation of antibodies against diverse antigens using sequence information alone. Next, we will cover how multimodal language models can further improve the ability to guide antibody evolution completely unsupervised.

11:30 Interactive Breakout Discussions

TABLE 8: AI/ML-Driven Design of Conditionally Active Molecules

Hunter Elliott, PhD, Senior Director, Machine Learning, BigHat Biosciences

• What is the therapeutic potential of conditional activity and how do we best balance this against increased complexity and risk?

- Which challenges are unique to ML-driven design of conditional molecules?
 How does the optimal ML toolkit vary between conditional and unconditional
- design?How can we best overcome challenges in data acquisition and availability?
- How can we best overcome challenges in data acquisition and availability? • What are the currently tractable forms of conditional activity and what can we
- envision for the future?

TABLE 9: Practical Impacts of Machine Learning on Biologics Preclinical Pipeline

Andrew B. Waight, PhD, Senior Director, Machine Learning, Discovery Biologics & Protein Sciences, Merck Research Labs

12:30 pm Session Break

6 | BioLogicSummit.com

12:40 LUNCHEON PRESENTATION: State Diagram Embeddings to Ground Protein Models in Physical Reality: Single Shot Biophysical Classification of Antibodies Shamit Shrivastava, CoFounder & CEO, Apoha

The Liquid Brain®, Apoha's novel physical ecosystem, introduces state diagrams: a new class of time-resolved, high-dimensional biophysical data that grounds AI/ ML protein models in physical reality. While existing data often fails to capture the dynamic, real-world behaviour of molecules, the Liquid Brain® seamlessly bridges this gap. Designed with an Al-first mindset, the Liquid Brain® directly interacts with samples to generate predictive insights. Using just 10µg of antibodies, it performs single-shot classification of developability risks, validated against 12 biophysical assays across 135 clinical-stage antibodies. In a customer study, it identified outliers in 70 VHH-Fc fragments with >80% accuracy via simple unsupervised algorithms and without any training. Our dataset of risk scores for 135 clinical stage antibodies is now available on Hugging Face.

Join us to discover how the Liquid Brain® can empower you with ML ready state diagram embeddings!

1:10 Ice Cream & Cookie Break in the Exhibit Hall with Last Chance for Poster Viewing

INTEGRATING AI/ML FOR ENHANCED ANTIBODY SELECTION AND DEVELOPABILITY

2:00 Chairperson's Remarks

M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business

2:05 Towards Enhancement of Antibody Thermostability and Affinity by Computational Design in the Absence of Antigen

Gilad Kaplan, PhD, Director, Biologics Engineering, AstraZeneca

DeepAb, a deep learning model for predicting antibody Fv structure directly from sequence, was used in conjunction with experimental deep mutational scanning (DMS) enrichment data to design 200 potentially optimized variants of an anti-hen egg lysozyme (HEL) antibody. We discuss the improvement rate of the designed clones for affinity, thermostability, and developability—and what the results would have been without using experimental DMS data to guide the design process.

2:35 Towards Optimal Clone Selection: Enhancing Antibody Discovery with AI/ML Approaches

Adrian Carr, PhD, Associate Director, Data Science, Al Innovation—Antibodies, Large Molecules Research (LMR), Sanofi

Optimal clone selection strikes a balance between selecting desirable antibody properties and diversity, aiming to maximize the range of targeted epitopes while minimizing redundancy. At Sanofi, we are exploring *in silico* screening, leveraging AI/ML methods to enhance success rates and accelerate the transition from discovery to lead. In parallel, generative AI can be used to augment natural and experimental repertoires, eliminating undesirable traits while preserving desirable characteristics.

3:05 PANEL DISCUSSION: AI DRIVEN OPTIMIZATION OF ANTIBODY PROPERTIES

Moderator: M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business

- · Where has there been the most benefit to cost or time savings?
- Are we noticing developability tools showing improvements in preclinical studies?
 - Are we noticing reduction in immunogenicity or timeline?
 - Where does *in silico* modeling allow us to remove experimental efforts and use computational modeling to replace?
 - · Have we seen benefits to the implementation of Federated Learning?
 - Are we seeing benefits to optimization and developability?

Panelists:

Hunter Elliott, PhD, Senior Director, Machine Learning, BigHat Biosciences Andrew B. Waight, PhD, Senior Director, Machine Learning, Discovery Biologics & Protein Sciences, Merck Research Labs

4:05 Close of BioLogic Summit



Machine Learning in Early Discovery

🕥 aureka

Exploiting the Power of ML in Early-Stage Biotherapeutic R&D

TUESDAY, JANUARY 14

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:20 Organizer's Remarks

Christina Lingham, Executive Director, Conferences and Fellow, Cambridge Healthtech Institute

Kent Simmons, Senior Conference Director, Cambridge Healthtech Institute



8:25 Plenary Keynote Introduction Maria Wendt, PhD, Global Head and Vice President, Digital and Biologics Strategy and Innovation, Sanofi



8:30 The State of the Art for Antibody Structure Prediction

Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo

Antibody structure prediction is pivotal for understanding antibody function and for enabling *in silico* antibody design. This lecture will outline current key advances as well as unresolved challenges in antibody structure prediction.



9:00 Design of New Protein Functions Using Deep Learning

David A. Baker, PhD, Henrietta & Aubrey David Endowed Professor, Biochemistry, University of Washington Proteins are biology's workhorses. Our goal is to create new

proteins that address current-day problems not faced during evolution. Rather than modify naturally occurring proteins, we design new ones from scratch to optimally solve the problem at hand. Increasingly, we develop and use deep learning methods to generate protein sequence, structure, and function. We then characterize these designed molecules experimentally. In this talk, I will describe several recent projects.

MACHINE LEARNING FOR TARGET IDENTIFICATION

10:00 Chairperson's Remarks

Brian Pierce, PhD, Associate Professor, Cell Biology & Molecular Genetics, Institute for Bioscience and Biotechnology Research, University of Maryland



10:05 KEYNOTE PRESENTATION: De novo Antibody

Design with RFantibody Nathaniel Bennett, PhD, Co-Founder, Xaira Therapeutics

Despite the central role that antibodies play in modern medicine, there is currently no way to rationally design novel antibodies

to bind a specific epitope on a target. I will discuss the development and experimental validation of RFantibody, a deep-learning pipeline capable of designing *de novo* antibodies that bind to user-specified epitopes.

10:35 Drug Target Prediction through Deep Learning Functional Representation of Gene Signatures

Hao Chen, PhD, Assistant Professor, University of Illinois Chicago

The L1000 program systematically generated 1.3 million gene expression signatures in human cell lines with diverse genomic and pharmacological perturbations. Similar L1000 gene signatures offer an unbiased data-driven mechanism to identify compound-target pairs. Current methods rely on matching gene identities when comparing gene signatures. We developed FRoGS, an approach that represents gene signatures projected onto their biological functions, instead of their identities, which results in more effective compound-target predictions.

11:05 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

11:20 Multi-Dimensional Functional Interrogation and Network Modeling of Tissue Tregs Reveals Novel Therapeutics for Autoimmunity and Inflammation

Ian Taylor, Director, Computational Biology, TRexBio

Our discovery biology platform provides a deep understanding of the regulatory circuits underlying human tissue Treg behavior. A suite of disease-relevant phenotypic assays facilitates multi-dimensional functional interrogation of key genes in human Tregs. These complex *in silico* tools combined with translational *in vitro* assays identify novel regulatory nodes and form the foundation of our growing pipeline of a new class of tissue Treg-focused therapeutics for immune-mediated diseases.

11:50 Spatial Proteomics and Virtual Cell Models

Emma Lundberg, PhD, Associate Professor, Bioengineering and Pathology, Stanford University

This research integrates bioimaging, proteomics, and AI to study human cell biology to explore protein distribution in time and space, investigating how localization variations affect cell functions and disease. Our goal is to create a spatiotemporal proteome model of a human cell. Using ML, we interpret spatial data from image collections and combine it with other datatypes to build whole-proteome multi-scale cell models, with potential to enhance drug discovery processes.

12:20 pm Redefining Therapeutic Possibilities: Aureka's Integrated AI and High-Throughput Platform for Antibody Innovation

Alon Wellner, VP Biology, Antibody Engineering, Aureka Biotechnologies Aureka Biotechnologies is advancing antibody development through an integrated platform that combines high-throughput biology with Al-driven multi-objective optimization. This unique approach enables the design of therapeutics with complex, challenging-to-engineer characteristics, addressing diverse therapeutic needs with precision. This presentation will explore how Aureka's platform is redefining possibilities in antibody engineering and driving the next generation of innovative therapeutics.

12:35 Enjoy Lunch on Your Own

1:30 Refreshment Break in the Exhibit Hall with Poster Viewing

MODELING FOR EARLY-STAGE DISCOVERY AND ENGINEERING

2:00 Chairperson's Remarks

Ian Taylor, Director, Computational Biology, TRexBio

2:05 AI-Empowered Antibody Discovery

Matthew Massett, PhD, Senior ML Scientist, Sanofi

Monoclonal antibodies are important biologics, but developing them is expensive and difficult since they must be specific and able to be produced at commercialscale. We present two transformer-based antibody language models, trained on large amounts of antibody data. These models can be used to inform and de-risk early antibody discovery.

2:35 Method Development and Application of Machine Learning to Engineer and Rapidly Reduce the Immunogenicity of Bacterial Proteases that Degrade Pathogenic Immunoglobulins

Jung-Eun (June) Shin, PhD, Machine Learning Scientist, Seismic Therapeutic We develop and apply machine learning models to optimize in parallel multiple drug-like properties of the bacterial enzyme IdeS, to design a therapeutic for chronic autoantibody-mediated diseases, while minimizing its immunogenicity and other liabilities. The success of this approach is demonstrated via *in vivo* and *in vitro* assays, and we illustrate its generalizability by engineering non-immunogenic bacterial cysteine proteases with a variety of immunoglobulin isotype specificities.

3:05 Use Case of CMC Development Digital Continuum

Dana I. Filoti, PhD, Associate Director of Scientific Architecture, Development Sciences Data and Digital Strategy, Abbvie

Analytical and formulation data is foundational to CMC Development. In this presentation we discuss AbbVie's CMC digital journey towards connecting analytical and formulation data to their respective study and sample ID, to build a data-driven CMC organization where structured data brakes silos





Machine Learning in Early Discovery

Exploiting the Power of ML in Early-Stage Biotherapeutic R&D

empowers storytelling visualizations that enable comparison across projects, reduces manual transcription to other systems and colleagues, and allowd for trending and other business metrics.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Interactive Breakout Discussions

TABLE 1: The Transition of Experimentalists into a Computational Paradigm in Pharmaceutical R&D

Qing Chai, PhD, Research Advisor, Biotechnology Discovery Research, Eli Lilly and Company

Addressing skills gaps

- Benchmarking progress compared with traditional structures
- Best practices for collaboration between experimentalists and data scientists
- Examples of successful transitions

· Implementing models/tools and workflows based on AI/ML approaches

5:30 RESP AI Model Accelerates Identification of Tight-Binding Antibodies

Wei Wang, PhD, Professor, Chemistry and Biochemistry, University of California San Diego

We present RESP2, an enhanced version of our RESP pipeline, designed for the discovery of antibodies against diverse antigens with simultaneously optimized developability properties. We used the RBD of the COVID-19 spike protein as a case study, and discover a highly human antibody with broad binding to different variants, which demonstrated the power of this pipeline for antibody discovery against a challenging target.

6:00 Assessing AlphaFold for Modeling Antibody and T Cell Receptor Recognition: Insights and Optimization Strategies

Brian Pierce, PhD, Associate Professor, Cell Biology & Molecular Genetics, Institute for Bioscience and Biotechnology Research, University of Maryland

Accurate modeling of immune recognition remains a major challenge in computational biology. To provide insights into the performance of deep learning for modeling immune recognition, we performed detailed benchmarking of multiple AlphaFold2 and AlphaFold3 approaches for modeling antibody and T cell receptor complexes. This revealed approaches with higher performance, overall limitations in success, as well the utility of confidence scores in the selection of accurate models.

6:30 Networking Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

WEDNESDAY, JANUARY 15

7:45 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Chairperson's Remarks

Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca



8:40 ML-Powered "Lab-in-the-Loop" Approach for Therapeutic Antibody Discovery and Optimization Vladimir Gligorijević, PhD, Senior Director, Al/ML Prescient Design, Genentech

In this talk, I will review our latest machine-learning approaches for antibody design and multi-property optimization that we use in our "Labin-the-Loop" (LitL) system. I will demonstrate how we use our LitL system to overcome some of the critical antibody design challenges and accelerate drug discovery programs.

NOVEL APPLICATIONS OF ML IN BIOPHARMACEUTICAL R&D

9:10 Session Break

9:15 Chairperson's Remarks

Wing Ki Wong, PhD, Senior Scientist, Pharmaceutical Research and Development, Large Molecule Research, Roche Diagnostics GmbH

9:20 Data- and Model-Guided Antibody and TCR Optimization

Arvind Sivasubramanian, PhD, Director, Computational Biology & Platform Technologies, Adimab LLC

We have developed an NGS-guided workflow for multi-dimensional optimization of biologics such as antibodies and TCRs. The workflow involves the rational design of targeted CDR combinatorial diversity guided by Deep Mutational Scanning, followed by yeast library selections. We will present antibody and TCR optimization case studies demonstrating substantial gain in affinity that is competitive with standard approaches, good developability, and minimal variant mutational load.

9:50 Repertoire Expansion for Antibody Discovery and Optimization Using Machine Learning Approaches

Wing Ki Wong, PhD, Senior Scientist, Pharmaceutical Research and Development, Large Molecule Research, Roche Diagnostics GmbH

In antibody discovery, repertoire sequencing unfolds a broad antigen-specific sequence space and informs of the potential mutational space. Integrating this information and advances in experimental techniques with different machine learning approaches, we are now able to efficiently explore and extend the sequence space to identify alternative binders and improve existing binders.

10:20 Using Machine Learning and Molecular Mimicry of Complex Biologies to Design New GLP-1 Agonists

Marcin Paduch, PhD, Vice President, Head of Platform Biology, Metaphore Biotechnologies

Targeting GPCRs with agonists is a significant challenge in biologics design. Our approach employs molecular mimicry to optimize both developability and functional outcomes, including biased agonism. Leveraging machine learning algorithms backed by extensive empirical data acquisition and protein engineering, we thoroughly explore the pharmacophore space within live cells. This enables us to create designer molecules that address complex biological processes, ultimately leading to the development of novel GLP1R modulators.

10:50 Bagel Booth Crawl with Coffee in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

PLENARY KEYNOTE SESSION

11:15 Chairperson's Remarks

Alissa Hummer, DPhil, Postdoctoral Fellow, Stanford University



11:20 Benchmarking and Integrating ML/AI Advancements in Biologics Discovery and Optimisation for Pharma

Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology,

AstraZeneca

11:50 FIRESIDE CHAT WITH PLENARY KEYNOTE



Moderator: Alissa Hummer, DPhil, Postdoctoral Fellow, Stanford University



Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca

12:20 pm Session Break

12:30 Luncheon Presentation (Sponsorship Opportunity Available) **or Enjoy Lunch on Your Own**

1:00 Close of Machine Learning in Early Discovery Conference

Training Data Generation and Quality

Ensuring Quality Predictions via Attention to Data Quality

WEDNESDAY, JANUARY 15

BENCHMARKING, BIAS, AND CONTROLS

1:30 pm Chairperson's Remarks

Arvind Sivasubramanian, PhD, Director, Computational Biology & Platform Technologies, Adimab LLC

1:35 Protein Language Models Are Biased by Unequal Sequence Sampling across the Tree of Life

Frances Ding, PhD, Machine Learning Scientist, Prescient Design, Genentech Protein language models (PLMs), like all machine learning models, learn biases from data. In this talk I will show that PLMs unintentionally learn a strong species bias. Specifically, PLM likelihoods of protein sequences from certain species (e.g., human, *E. coli*) are systematically higher, independent of the protein in question. I trace this bias's origins and demonstrate how it can be detrimental for some protein design applications, such as enhancing thermostability.

2:05 Data-efficient Training of Natively Paired Antibody Language Models Bryan Briney, PhD, Assistant Professor, Immunology & Microbial Science, Scripps Research Institute

Antibody language models training using natively paired data outperform unpaired models, likely due to their ability to learn structurally and functionally relevant cross-chain patterns. Unfortunately, severe data constraints hinder our ability to scale model size and performance. We have evaluated several training techniques for maximizing the training value of every training example to construct a highly data-efficient strategy for antibody language model training.

2:35 Refreshment Break in the Exhibit Hall with Poster Viewing

3:10 AI Benchmarking Competition Based on High-Throughput Automation and Cloud Lab Experimentation

Peter Kelly, Director, Open Datasets Initiative, Align to Innovate

Align to Innovate, a non-profit research organization, is on a mission to shepherd biology into a data-first discipline through reproducible, scalable, and sharable experimentation. We run a suite of programs that work in conjunction to develop automated wet-lab experimental methods accessible to the community, collect large-scale public protein engineering datasets, and benchmark predictive and generative protein design algorithms. All our work is community-driven, collaborative, and operates under open science principals.

HIGH-THROUGHPUT EXPERIMENTATION



3:40 KEYNOTE PRESENTATION: Generation of High-Quality Aggregation Propensity Datasets for Machine Learning by Deep Mutational Scanning and an *in vivo* Assav

David J. Brockwell, PhD, Professor, School of Molecular and Cellular Biology, University of Leeds

A key requisite of any machine learning campaign is the availability of large volumes of high-quality training data that reports on the property to be predicted. Here we show that a tripartite beta-lactamase assay previously used by our group as a directed evolution screen can be reconfigured into a deep mutational screening format, providing datasets that can subsequently be used to train predictive models for different biophysical properties.



4:10 FEATURED PRESENTATION: High-Throughput Data Generation and Experimental Validation

Gabriel J. Rocklin, PhD, Assistant Professor, Pharmacology, Northwestern University

All proteins continuously fluctuate between different conformational states according to the energies of these states and the barriers between

them. Even rare, high-energy states can have large impacts on protein function, aggregation, immunogenicity, and more. These high-energy states are challenging to observe and have never been examined at scale. Using a new high-throughput approach, we quantified protein energy landscapes for 5,000 domains and applied these data to guide protein engineering.

4:40 Design of Multifunctional Antibodies with Generative AI and Highthroughput Data Iteration

Wei Lu, PhD, Director, Al Drug Design, Aureka Biotechnologies, Inc.

Our generative protein design system combines structure-informed protein models with high-throughput digital biotechnology for scalable functional antibody design. In an obesity therapeutic case, dual-binding antibodies created with this system achieved sub-picomolar potency, surpassing current candidates by 50-fold and clinical benchmarks on early metrics. From design to characterization, the process took under 9 weeks, showcasing a practical, data-driven approach to next-generation therapeutics with minimal experimental overhead.

SPECIAL PRESENTATION

5:10 *In Vitro* Validated Antibody Design Against Multiple Therapeutic Antigens Using Inverse Folding

Amir P. Shanehsazzadeh, Artificial Intelligence Scientist, Absci Corp.

We present an antibody inverse-folding model and demonstrate its application in binder design against 8 therapeutic antigens. For each antigen, we design 100 HCDR3s and 100 HCDR123s using a native antibody-antigen structure, scaffold them into the native antibody, screen using SPR, and identify binders. Inverse-folding has applications to *de novo* design and lead optimization, and the data from this study are a useful benchmark of antibody-antigen interactions.

5:40 Close of Day

Wednesday Night Meet-Up

IN PERSON ONLY MEETUP: What Needs to be Done to Make a Pipeline of Mini-Binders More Developable?



Monica L. Fernandez-Quintero, PhD, Staff Scientist, General Inorganic & Theoretical Chemistry, Scripps Research

Institute Wing Ki Wong, PhD, Senior Scientist, Pharmaceutical Research and Development, Large Molecule Research, Roche Diagnostics GmbH

THURSDAY, JANUARY 16

7:45 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION

8:15 Chairperson's Remarks

M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, an IQVIA business



8:20 Transforming Therapeutic Protein Engineering Marissa Mock, PhD, Senior Research Director, Amgen Inc. Generative biology is an emerging discipline that integrates artificial intelligence (AI) and machine learning (ML) with advanced life science technologies. The application of

generative biology to protein engineering is accelerating the discovery and design of complex proteins with therapeutic potential—and, maximizing the benefits of these novel technologies will require seamless integration of both wet- and dry-laboratory technologies.

8:50 Session Break

DATASET TRAINING FOR SPECIFIC MODELS AND EXPERIMENTS

8:55 Chairperson's Remarks

Bismark Amofah, PhD, Senior Scientist, Biologics Engineering, AstraZeneca

9:00 Training Data Requirements for Antibody-Antigen Binding Affinity Prediction under Multiple Circumstances

Alissa Hummer, DPhil, Postdoctoral Fellow, Stanford University

Antibodies are an important class of medicines, whose efficacy is driven by specific target binding. Given the therapeutic relevance, there have been multiple attempts to predict antibody-antigen binding affinity computationally. I will discuss

Training Data Generation and Quality

Ensuring Quality Predictions via Attention to Data Quality

our findings on how training data influences the success and selection of machine learning strategies to tackle this challenge, ranging from antigen-specific to generalizable and zero-shot affinity prediction.

9:30 Enhanced Prediction of Protein-Protein Interface Structure via Augmentation with *in vitro* Affinity Data

David Noble, Data Scientist II, A Alpha Bio Inc.

The structural complex of a PPI can yield important mechanistic insights that support drug discovery efforts. Predictive models such as AlphaFold multimer remain poor quality for difficult but clinically significant systems. Here we present AFInjection, a framework for generating and incorporating *in vitro* experimental data simulating coevolution to AlphaFold to significantly improve complex prediction. We demonstrate the utility of this method on antibody-antigen systems and weak PPIs with disordered regions.

10:00 Featured Poster Presentation: Leveraging Novel *In Vivo* Datasets to Generate Machine Learning Models Predicting Protein Aggregation and Developability

Conor McKay, Researcher, Astbury Centre for Structural Molecular Biology, University of Leeds

Protein aggregation impacts neurodegenerative diseases and biotherapeutic manufacturing. Big data tools like AlphaFold and protein language models excel in biology but rely heavily on high-quality training datasets. This work introduces the tripartite β -lactamase assay, a novel method for generating large, high-quality datasets that link protein aggregation to cell survival, enabling deeper insights into protein behavior and aggregation-related challenges.

10:15 Featured Poster Presentation: Mimic Antibodies and How to Find Them

Brennan Abanades, PhD, Postdoctoral Fellow, Large Molecule Research, Roche The majority of antibodies in the PDB targeting the same binding site as some other non-antibody proteins are mimic antibodies– they share with the other protein a motif composed of key residues at conserved geometrical positions. By investigating mimic antibodies and how they imitate the binding site of other proteins, we develop a method for identifying them in repertoire data and validate it on IL-18RA.

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 Validating High Throughput Developability Assays to Support ML Model Training

Bismark Amofah, PhD, Senior Scientist, Biologics Engineering, AstraZeneca Classic developability assays are low-medium throughput and require complex reagent generation. The large, normalized datasets required for ML tool building require adapting or replacing these assays with ones amenable to high throughput automation. We describe our process and results for validating replacement HT developability assays and a HT developability package compatible with very early HT screening.

11:30 Interactive Breakout Discussions

TABLE 5: Internal Data Generation and Curation

Kevin Metcalf, PhD, Associate Principal Scientist, Merck & Co., Inc.

- Amplification strategies
 Avoiding bias
- Controls and validation
 Dealing with skewed data
- Historical data
- TABLE 6: Machine Learning in Biologic Drug Discovery: Leveraging External Data Sources

David Noble, Data Scientist II, A Alpha Bio Inc.

• Quality: Diversity, leakage, reproducibility, quality vs. quantity

Collaborative data generation: Industry-academia partnerships, data sharing consortia

Federated learning: Technical challenges, open-source foundation models
 Intellectual property: Data ownership, balancing openness with commercial

interests

Open-source data: Curation quality, integrating diverse sources with proprietary data

12:30 pm Session Break

Closed-loop experimentation

12:40 LUNCHEON PRESENTATION: State Diagram Embeddings to Ground Protein Models in Physical Reality: $\Lambda POH\Lambda$ Single Shot Biophysical Classification of Antibodies

Shamit Shrivastava, CoFounder & CEO, Apoha

The Liquid Brain®, Apoha's novel physical ecosystem, introduces state diagrams: a new class of time-resolved, high-dimensional biophysical data that grounds AI/ ML protein models in physical reality. While existing data often fails to capture the dynamic, real-world behaviour of molecules, the Liquid Brain® seamlessly bridges this gap. Designed with an AI-first mindset, the Liquid Brain® directly interacts with samples to generate predictive insights. Using just 10µg of antibodies, it performs single-shot classification of developability risks, validated against 12 biophysical assays across 135 clinical-stage antibodies. In a customer study, it identified outliers in 70 VHH-Fc fragments with >80% accuracy via simple unsupervised algorithms and without any training. Our dataset of risk scores for 135 clinical stage antibodies is now available on Hugging Face.

Join us to discover how the Liquid Brain® can empower you with ML ready state diagram embeddings!

1:10 Ice Cream & Cookie Break in the Exhibit Hall with Last Chance for Poster Viewing

DATASET GENERATION AND CURATION

2:00 Chairperson's Remarks

Winston Haynes, PhD, Head, Data Science & Machine Learning, LabGenius Ltd.

2:05 Curation Strategies for R&D Pipeline Data

Kevin Metcalf, PhD, Associate Principal Scientist, Merck & Co., Inc.

Model-based prediction of biologics developability properties will increase speed to clinic. Previous pipeline program data is a valuable data source for training models but requires data curation, contextualization, annotation, and quality control for this new use. I will describe how we incorporated historical data using data quality control protocols to create reusable data products for machine learning prediction of key attributes, including hydrophobicity and polyspecificity of monoclonal antibodies.

2:35 ML Models for Nanobody Developability trained on a Purpose-Built Multi-Readout Dataset

Samuel Demharter, PhD, Senior Data Scientist, Discovery Data Science and Protein Science & Technologies, Genmab

The biophysical characterisation of biologics requires significant wet-lab resources. To enable large-scale predictions of millions of molecules, proteinlanguage models have become an attractive proposition to accurately predict lab readouts. However, current machine-learning models are limited in accuracy largely due to lack of high-quality and high-volume training data. In this talk, we present the generation of a maximally informative dataset for the purpose of training machine-learning models for nanobody developability predictions.

3:05 A Machine Learning-Driven Approach for Multi-Parametric Optimization of T Cell Engagers

Winston Haynes, PhD, Head, Data Science & Machine Learning, LabGenius Ltd. T cell engagers (TCEs) promise breakthroughs in the treatment of solid tumors, but their progression in the clinic is limited by on-target, off-tumor toxicity. In this talk, I describe how our platform integrates active learning, automation, and high-throughput functional assays to efficiently identify highly selective and potent TCEs. I highlight our utilization of the design-build-test-learn ecosystem to generate high-quality data that powers our machine learning models and therapeutic assets.

3:35 Improving AlphaFold2 Performance with a Global Metagenomic & Biological Data Supply Chain

Geraldene Munsamy, PhD, Senior Scientist, Deep Learning, Basecamp Research Ltd. Scaling laws estimate over a trillion species exist, yet less than 0.00001% have been studied. Powered by a global metagenomic data supply chain, BaseFold offers improved protein structure prediction with increased accuracy, achieving up to 80% reductions in RMSD values. Leading to more reliable predictions, better docking results, and advancements in therapeutic development, all while incentivizing biodiversity protection.

4:05 Close of BioLogic Summit

10 | BioLogicSummit.com



HOTEL AND TRAVEL

CONFERENCE VENUE AND HOTEL:

Hilton San Diego Bayfront 1 Park Boulevard San Diego, CA 92101

Discounted Room Rate: \$296 s/d includes complimentary Wi-Fi Discounted Room Rate Cut-off Date: December 16, 2024

VISIT THE TRAVEL PAGE of BioLogicSummit.com to make your hotel reservations and for additional information



off the Conference Registration by reserving your Hotel Room with the Hilton San Diego Bayfront! Your reservation must be made under the PepTalk/ BioLogic Room block for a minimum of 4 nights. Must be reserved by December 16, 2024.

Only one discount applicable per hotel room.

Can't Make it to San Diego?

Connect from anywhere. Join via our robust virtual platform and access these dynamic features. INTUITIVE INTERFACE COMPANY BRANDING



LOGO

DOWNLOADS

LIVE CHAT

LIVE SESSIONS RECORDED SESSIONS POSTER SESSIONS PANEL DISCUSSIONS





Present a Poster and Save \$50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure an onsite poster board and/or ensure your poster is included in the conference materials, your full submission must be received, and your registration paid in full by November 22, 2024. Register and indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your materials. Please see below for more information.

Reasons you should present your research poster at this conference:

- Your research will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
- Discuss your research and collaborate with other attendees
- Your poster will be published in our conference materials
- Receive \$50 off your registration

SPONSORSHIP PROGRAMS

CHI's comprehensive sponsorship packages allow you to achieve your objectives before, during, and long after the event. Maximize exposure to hard-to-reach decision-makers through the following sponsorship opportunities:

PODIUM PRESENTATIONS - AVAILABLE WITHIN MAIN AGENDA!

Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program. Package includes exhibit space, onsite branding, and access to cooperative marketing efforts by CHI.

ONE-ON-ONE MEETINGS

Work with us to identify your target prospects and we will schedule meetings for you. Think of us as your inside sales team with all your hottest leads in close reach. Opportunities sold on a very limited basis.

INVITATION-ONLY DINNER/HOSPITALITY SUITE

Sponsors will select their top prospects from the conference preregistration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations, conduct follow-up, and confirm attendees. The evening will be customized to meet with your specific objectives.

CORPORATE SUPPORT EXHIBIT PACKAGE

Includes 8'x10' exhibit space. Contact us for more information.

ADDITIONAL SPONSORSHIP & BRANDING OPPORTUNITIES INCLUDE:

- Meter Boards
- Lanyards
- Keynote Chair Drop
- Tote Bag Exclusive Sponsorship
- Water Bottles
- Conference Track Notebooks
- Tote Bag Insert
- And more!

FOR MORE INFORMATION REGARDING SPONSORSHIP OPPORTUNITIES, PLEASE CONTACT:

COMPANIES A-K Jason Gerardi Sr. Manager, Business Development 781-972-5452 jgerardi@healthtech.com COMPANIES L-Z Ashley Parsons Manager, Business Development 781-972-1340 ashleyparsons@healthtech.com

2025 Sponsor Prospectus Available Online ->

Includes Access to **SPEPTALK** The Protein Science and Production Week

PRICING AND REGISTRATION INFORMATION

JMMIT 2025

ALL-ACCESS PRICING (Includes access to ALL conferences, training seminars, and networking events from Monday-Thursday. Plus, virtual and on-demand access for one year)	Commercial	Academic, Government, Hospital-affiliated
Advance Rate until December 20, 2024	\$3199	\$1549
Registrations after December 20, 2024	\$3399	\$1699
STANDARD CONFERENCE PRICING (Includes access to TWO conferences a	and networking events, Tuesday - Thursday. I	Plus, virtual and on-demand access for one year)
Advance Rate until December 20, 2024	\$2699	\$1299
Registrations after December 20, 2024	\$2899	\$1399
BASIC CONFERENCE PRICING (Includes access to ONE conference and ne	tworking events. Plus, virtual and on-demand	l access for one year)
Advance Rate until December 20, 2024	\$2199	\$1099
Registrations after December 20, 2024	\$2399	\$1199
ONE-DAY TRAINING SEMINAR-ONLY PRICING (Includes in-person access	to One-Day Training Seminar only)	

CONFERENCE DISCOUNTS

Poster Submission - Discount (\$50 Off): Poster materials are due by November 22, 2024. Once your registration has been fully processed, we will send an email containing a unique link and instructions for submitting your abstract and other materials. If you do not receive your link within 5 business days, please contact **jring@healthtech.com.** * We reserve the right to publish your poster content in various marketing materials and products.

Alumni Discount - SAVE 20%: CHI appreciates your participation at PEGS and PepTalk. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

Group Discounts: Have your colleagues or entire team attend. Purchase a full price registration and participants from the same organization will receive a 20% discount when registering through the Group Registration page. For more information on group discounts contact Bill Mote at 781-972-5479.

How to Register: BioLogicSummit.com

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode **AIBP F** when registering!

Please refer to the Registration Code below:



A Division of Cambridge Innovation Institute

250 First Avenue, Suite 300 Needham, MA 02494 Healthtech.com Fax: 781-972-5425